Absence of Mutations in the CDKN2 Binding Site of CDK4 in Childhood Acute Lymphoblastic Leukemia

References

• Sherr C. J. Cancer cell cycles. Science 1996; 274: 1672–7
   PubMed Web of Science ®Google Scholar
• Weinberg R. A. The retinoblastoma protein and cell cycle control. Cell 1995; 81: 323–30
   PubMed Web of Science ®Google Scholar
• Chellappan S. P., Hiebert S., Mudryj M., Horowitz J. M., Nevins J. R. The E2F transcription factor is a cellular target for the RB protein. Cell 1991; 65: 1053–61
   PubMed Web of Science ®Google Scholar
• Hannon G. J., Beach D. p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature 1994; 371: 257–61
   PubMed Web of Science ®Google Scholar
• Horowitz J. M., Park S. H., Bogenmann E., Cheng J. C., Yandell D. W., Kaye F. J., Minna J. D., Dryja T. P., Weinberg R. A. Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. Proc Natl Acad Sci USA 1990; 87: 2775–9
   PubMed Web of Science ®Google Scholar
• Jiang W., Kahn S. M., Tomita N., Zhang Y. J., Lu S. H., Weinstein I. B. Amplification and expression of the human cyclin D gene in esophageal cancer. Cancer Res 1992; 52: 2980–3
   PubMed Web of Science ®Google Scholar
• Schmidt E. E., Ichimura K., Reifenberger G., Collins V. P. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 1994; 54: 6321–4
   PubMed Web of Science ®Google Scholar
• He J., Allen J. R., Collins V. P.M. J., Allalunis Turner Godbout R., Day R. S., 3rd, James C. D. CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res 1994; 54: 5804–7
   PubMed Web of Science ®Google Scholar
• Tsao H., Benoit E., Sober A. J., Thiele C., Haluska F. G. Novel mutations in the p16/CDKN2A binding region of the cyclin-dependent kinase-4 gene. Cancer Res 1998; 58: 109–13
   PubMed Web of Science ®Google Scholar
• Nobori T., Miura K., Wu D. J., Lois A., Takabayashi K., Carson D. A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994; 368: 753–6
   PubMed Web of Science ®Google Scholar
• Kamb A., Gruis N. A., Weaver-Feldhaus J., Liu Q., Harshman K., Tavtigian S. V., Stockert E., Day R. S., 3rd, Johnson B. E., Skolnick M. H. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264: 436–40
   PubMed Web of Science ®Google Scholar
• Spruck C. H., 3rd, Gonzalez-Zulueta M., Shibata A., Simoneau A. R., Lin M. F., Gonzales F., Tsai Y. C., Jones P. A. p16 gene in uncultured tumours. Nature 1994; 370: 183–4
   PubMed Web of Science ®Google Scholar
• Cayuela J. M., Madani A., Sanhes L., Stern M. H., Sigaux F. Multiple tumor-suppressor gene 1 inactivation is the most frequent genetic alteration in T-cell acute lymphoblastic leukemia. Blood 1996; 87: 2180–6
   PubMed Web of Science ®Google Scholar
• Takeuchi S., Bartram C. R., Seriu T., Miller C. W., Tobler A., Janssen J. W., Reiter A., Ludwig W. D., Zimmermann M., Schwaller J. Analysis of a family of cyclin-dependent kinase inhibitors: p15/MTS2/INK4B, p16/MTS1/INK4A, and p18 genes in acute lymphoblastic leukemia of childhood. Blood 1995; 86: 755–60
   PubMed Web of Science ®Google Scholar
• Rasool O., Heyman M., Brandter L. B., Liu Y., Grander D., Söderhall S., Einhorn S. p15ink4B and p16ink4 gene inactivation in acute lymphocytic leukemia. Blood 1995; 85: 3431–6
   PubMed Web of Science ®Google Scholar
• Batova A., Diccianni M. B., Yu J. C., Nobori T., Link M. P., Pullen J., Yu A. L. Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell acute lymphoblastic leukemia. Cancer Res 1997; 57: 832–6
   PubMed Web of Science ®Google Scholar
• Herman J. G., Jen J., Merlo A., Baylin S. B. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res 1996; 56: 722–7
   PubMed Web of Science ®Google Scholar
• Drexler H. G. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia 1998; 12: 845–59
   PubMed Web of Science ®Google Scholar
• Zuo L., Weger J., Yang Q., Goldstein A. M., Tucker M. A., Walker G. J., Hayward N., Dracopoli N. C. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 1996; 12: 97–9
   PubMed Web of Science ®Google Scholar
• Wölfel T., Hauer M., Schneider J., Serrano M., Wölfel C., Klehmann-Hieb E., De Plaen E., Hankeln T., Meyer zum Buschenfelde K. H., Beach D. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995; 269: 1281–4
   PubMed Web of Science ®Google Scholar
• Guldberg P., Kirkin A. F., Gronbaek K., Straten P., Ahrenkiel V., Zeuthen J. Complete scanning of the CDK4 gene by denaturing gradient gel electrophoresis: a novel missense mutation but low overall frequency of mutations in sporadic metastatic malignant melanoma. Int J Cancer 1997; 72: 780–3
   PubMed Web of Science ®Google Scholar
• Soufir N., Avril M. F., Chompret A., Demenais F., Bombled J., Spatz A., Stoppa-Lyonnet D., Benard J., Bressac-de Paillerets B. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. Hum Mol Genet 1998; 7: 209–16
   PubMed Web of Science ®Google Scholar
• Reiter A., Schrappe M., Ludwig W. D., Hiddemann W., Sauter S., Henze G., Zimmermann M., Lampert F., Havers W., Niethammer D. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994; 84: 3122–33
   PubMed Web of Science ®Google Scholar
• Henze G., Fengler R., Hartmann R., Kornhuber B., Janka-Schaub G., Niethammer D., Riehm H. Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM group. Blood 1991; 78: 1166–72
   PubMed Web of Science ®Google Scholar
• Taube T., Seeger K., Beyermann B., Hanel C., Duda S., Linderkamp C., Henze G. Multiplex PCR for simultaneous detection of the most frequent T cell receptor-delta gene rearrangements in childhood ALL. Leukemia 1997; 11: 1978–82
   PubMed Web of Science ®Google Scholar
• FitzGerald M. G., Harkin D. P., Silva-Arrieta S., Mac-Donald D. J., Lucchina L. C., Unsal H., O'Neill E., Koh J., Finkelstein D. M., Isselbacher K. J., Sober A. J., Haber D. A. Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. Proc Natl Acad Sci USA 1996; 93: 8541–5
   PubMed Web of Science ®Google Scholar
• Flores J. F., Pollock P. M., Walker G. J., Glendening J. M., Lin A. H., Palmer J. M., Walters M. K., Hayward N. K., Fountain J. W. Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds. Oncogene 1997; 15: 2999–3005
   PubMed Web of Science ®Google Scholar
• Piccinin S., Doglioni C., Maestro R., Vukosavljevic T., Gasparotto D., D'Orazi C., Boiocchi M. p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression. Int J Cancer 1997; 74: 26–30
   PubMed Web of Science ®Google Scholar